Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes

Trapp BD Peterson J Ransohoff RM . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

Tedeschi G Lavorgna L Russo P . Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280–285.

Amato MP Portaccio E Goretti B . Association of neocortical volume changes with cognitive deterioration in relapsing–remitting multiple sclerosis. Arch Neurol 2007; 64: 1157–1161.

Giorgio A Battaglini M Smith SM . Brain atrophy assessment in multiple sclerosis: Importance and limitations. Neuroimaging Clin N Am 2008; 18: 675–686.

Fisher E Measurement of CNS atrophy. In: Cohen JA Rudick RA (eds) Multiple Sclerosis Therapeutics. 4th ed. Cambridge: Cambridge University Press, 2011. pp.128–149.

Fisher E Rudick RA Simon JH . Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412–1420.

Rudick RA Fisher E Lee JC . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698–1704.

Miller DH Soon D Fernando KT . MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68: 1390–1401.

Zivadinov R Reder AT Filippi M . Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136–144.

Kapoor R Furby J Hayton T . Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681–688.